Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
CHINA PHARMA HOLDINGS, INC. issued 12,600,000 restricted shares of common stock to Xiaoyan Zhang or designated third party for $6.93 million at $0.55 per share.
- Security
- common stock
- Shares
- 12,600,000 restricted shares
- Purchaser
- Xiaoyan Zhang or designated third party
- Consideration
- $6.93 million at $0.55 per share
Exact text from the filing
research and development, writing of registration materials, registration application and other technical services. The transfer price as contemplated by the Agreement is $6.93 million, which will be paid in the form of common stock of the Company, par value $0.001 per share, at $0.55 per share. echnical services. The transfer price as contemplated by the
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
CHINA PHARMA HOLDINGS, INC. entered into Technology Transfer Agreement with Xiaoyan Zhang valued at $6.93 million (effective 2026-02-26).
- Action
- entry
- Agreement
- asset purchase
- Counterparty
- Xiaoyan Zhang
- Value
- $6.93 million
- Effective
- 2026-02-26
Exact text from the filing
On February 26, 2026 (the “Signing Date”), Hainan Helpson Medical & Biotechnology Co., Ltd (“ Helpson ”), a wholly owned subsidiary of China Pharma Holdings, Inc. (the “ Company ”), entered into a Technology Transfer Agreement (the “ Agreement ”) with Xiaoyan Zhang (the “ Transferor ”). The Transferor owns an invention patent of an Prinsepia Utilis Esterol Sublingual Tablets and Method for Its Preparation (the “ Invention Patent ”). Pursuant to the Agreement, the Transferor will transfer the ownership of the Invention Patent to Helpson. The Transferor or its designated third party shall provide relevant technical services, which include but are not limited to product research and development, writing of registration materials, registration application and other technical services. The transfer price as contemplated by the Agreement is $6.93 million, which will be paid in the form of common stock of the Company, par value $0.001 per share, at $0.55 per share.
View on SEC.gov